Business
Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the closing of a $70M Series C1 financing.
About this update from Talon Capital Corp.
[{"type":"text","content":"SHANGHAI and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the closing of a $70M Series C1 financing.","length":256,"tagName":"p"},{"type":"text","content":"The round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and a leading global healthcare fund, with participation from a sovereign wealth fund, NGS Super (NGS), E-Town Capital, Elikon Venture, and Talon Capital. Proceeds will accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving ways to commercialization.","length":431,"tagName":"p"},{"type":"text","content":"Oricell is advancing a differentiated pipeline of CAR-T cell therapies for solid tumors, underpinned by three proprietary platforms developed over the past decade:","length":163,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Ori®Ab: antibody discovery and engineering library","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"Ori®Armoring: enhancement of T-cell persistence and other crucial functions by TAs（Therapeutic Areas）","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"OnGo (Fast) CMC: rapid, scalable and effective manufacturing","length":60,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":211,"olType":false},{"type":"text","content":"Oricell has generated proof-of-concept (POC) clinical data across multiple pipeline CAR-T products. Its lead program, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma (HCC). Both a Phase I Investigator-Initiated Trial (IIT) and a Phase I IND study of Ori-C101 are completed. With far-leading-industry efficacy and safety profile, Ori-C101's clinical data have been featured at major academic conferences such as ASCO 2021 and ASCO 2025. Ori-C101 is entering the registrational pivotal trial and is well positioned to become the world's first approved CAR-T therapy for HCC.","length":625,"tagName":"p"},{"type":"text","content":"Beyond Ori-C101, Oricell's integrated platforms are also yielding multiple next-generation CAR-T products with multi-targets and multi-mechanism designs. The innovative se...